Hoth Therapeutics, Inc. Stock price
Is Hoth Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
Hoth Therapeutics, Inc. Stock Analysis
Analyst Opinions
7 Analysts have issued a Hoth Therapeutics, Inc. forecast:
Analyst Opinions
7 Analysts have issued a Hoth Therapeutics, Inc. forecast:
Don't miss a Thing! We will send you all news about Hoth Therapeutics, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Hoth Therapeutics, Inc. Stock News
Company Profile
Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.
| Head office | United States |
| CEO | Mr. Knie |
| Employees | 3 |
| Founded | 2017 |
| Website | hoththerapeutics.com |


